Avenue Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Avenue Therapeutics

04/08/2023 19:32

* Avenue Therapeutics Inc  ATXI.OQ   ATXI.O  is expected
to report
results on August 7 (estimated).
    * 
    * ​Refinitiv's mean analyst estimate for Avenue Therapeutics
Inc
is for a loss of 29 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Avenue
Therapeutics Inc is $32​, above​ its last closing price
of $1.09. ​​​

This summary was machine generated August 4 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated